ALK+ lymphoma: clinico-pathological findings and outcome.
Brunangelo Falini(University of Perugia), Antonella Santucci(University of Perugia), Marco Fizzotti(University of Perugia), Vittorina Zagonel(Istituto Oncologico Veneto), Stefano Pileri(European Institute of Oncology), Antonino Carbone(Centro di Riferimento Oncologico), Fabio Menestrina(University of Verona), Antonella Aiello(University of Perugia), Pier Giuseppe Pelicci(Office of Technology Transfer), Iguacyra Araujo(University of Perugia), Leonardo Flenghi(University of Perugia), Maria Paola Martelli(University of Perugia), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Mario Lazzarino, R Giardini(University of Perugia), Hans Dieter Foss(University of Perugia), Gregor Verhoef(Universitair Ziekenhuis Leuven), Chris De Wolf‐Peeters(University of Perugia), Giuseppe Todeschini(University of Pisa), Marco Paulli(University of Milan)
Cited by 569
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
|Nature reviews. Cancer|2006|2.2k
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
|New England Journal of Medicine|2005|1.9k